White Blood Cell Growth Factors
Key Points
Key Points
Primary prophylaxis is recommended for the prevention of febrile neutropenia in patients who are at high risk on the basis of age, medical history, disease characteristics, and myelotoxicity of the chemotherapy regimen.
Dose-dense regimens that require CSFs should be used only within an appropriately designed clinical trial or if supported by convincing efficacy data.
Current recommendations for the management of patients exposed to lethal doses of total-body radiotherapy, but not doses high enough to lead to certain death as a result of injury to other organs, include the prompt administration of CSFs.
Diagnosis
...agnosis...
...1. Patient Risk Factors for Febri...
...ent Risk Factors for Poor Clinical Outcomes Re...
Treatment for Adult Patients
Treatment for Adult...
...prophylaxis with a CSF starting wi...
...ary prophylaxis with a CSF is recommen...
...SFs should not be routinely used for...
...hould not be routinely used as adjunctive...
...breast cancer and lymphoma] ( EB , H...
...l cancer] ( EB , H , H , M )3336...
...d alone, after chemotherapy, or in...
...e administered after autologous st...
...e administered after allogeneic stem-cell tr...
...SFs for patients with diffuse aggressive lymphom...
...ilgrastim, tbo-filgrastim, and filgrastim-sndz (a...
...dations for the management of patients...
Treatment for Pediatric Patients
...reatment for Pediatric Patients...
...use of CSFs in pediatric patients will almost alw...
...ic indications in which dose-intense chemot...
...t be used in pediatric patients with nonrelaps...
Table 3. Dosing and Administration of CSFs
...le 3. Dosing and Administration of CSFsHav...